The availability of genetic testing for cardiomyopathies in Italy
The results of a survey on the availability of genetic testing at the main Italian laboratories of Medical Genetics of the SSN ...
What happens when we take a drug: Placebo and Nocebo effects
Whenever a drug is used for the first time in the treatment of diseases, the patient is faced with ...
Mavacamten ready for “compassionate use”, perhaps in a year it will be refundable
Mavacamten and Aficamten are the two new drugs for the treatment of Hypertrophic Cardiomyopathy. Mavacamten has entered the phase of use ...
To implant a defibrillator or not? AICARM NEWS thematic sheet
A new fact sheet for AICARM members. Emil Tsenov, entrepreneur and author of the novel “The Green Tunnel”, which tells ...
Should I implant a defibrillator or not? The patient's perspective
For a patient with a genetic heart disease, the decision to implant a defibrillator is not easy. The pros ...
Cardiac arrest: how to improve complication-free survival after cardiopulmonary resuscitation (CPR)
Reflections on a study published in the Journal of the American College of Cardiology that reports the evolution of the incidence, management and ...
Green light for Mavacamten: the compassionate use phase begins
Mavacamten is the first approved drug in a new class of drugs that reduce the activity of “cardiac myosin,” a ...
Shortage of the drug Nadolol: AICARM requests the intervention of AIFA
The shortage of Nadolol in pharmacies is increasingly worrying doctors and patients and for this reason AICARM APS has decided ...
Life in your hands: the importance of cardiopulmonary resuscitation for families of patients with cardiomyopathy
Cardiac arrest is a reality feared by everyone, however people with a form of cardiomyopathy are at risk ...
NADOLOL, import of the drug and galenic preparation
According to AIFA, Nadolol will return to the market next March 2024. In the meantime, patients who use Nadolol can ...